All posts tagged "Osteotech"

  • Biologics
    Osteotech Reports Stockholders Approve Acquisition by Medtronic

    EATONTOWN, N.J., Nov. 10, 2010 /PRNewswire-FirstCall/ — Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that at a special meeting of stockholders held yesterday, Osteotech’s stockholders approved Medtronic, Inc.’s acquisition of Osteotech for $6.50 in cash for each share of Osteotech common stock outstanding, which per share...

  • Uncategorized
    Medtronic Signs Agreement to Acquire Osteotech

    Just when we thought we would see some interesting theater within Osteotech, we were right. I wonder if this is what the BOD dispute was about the entire time. Click below to read the entire press release.

  • Uncategorized
    Pound for Pound

    This has been an interesting week in Spine/Biologics. You may remember when Ramius decided to go on the offensive against Orthofix last year regarding the perceived mismanagement/acquisition of Blackstone. Apparently, some other investors thought highly of that tactic as investors of Alphatec and Osteotech have decided to employ a similar strategy. Osteotech...

  • Uncategorized
    Osteotech girds for rumble with dissident investors

    There’s a fight brewing in Eatontown, N.J., over who will get to determine the future direction of Osteotech Inc. (NSDQ:OSTE), as a group of dissident investors looks to elect its own slate of directors to the company’s board. Ahead of a planned shareholders’ meeting August 23, the dissidents — Spencer Capital Opportunity...

  • Biologics
    Osteotech Discloses Ongoing Engagement of Deutsche Bank Focused on Evaluating Strategic Alternatives

    EATONTOWN, N.J., Aug. 9 /PRNewswire-FirstCall/ — Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, disclosed today that its Board of Directors engaged Deutsche Bank Securities Inc. in 2009 as its exclusive financial advisor to assist in the identification and evaluation of a range of strategic alternatives focused...

  • Financial
    Osteotech Reports Second Quarter 2010 Financial Results

    OSTEOTECH, INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (dollars in thousands, except per share data) (unaudited) Three Months Six Months Ending June 30, Ending June 30, 2010 2009 2010 2009 Revenue $   23,997 $      23,471 $      46,524 $      47,402 Cost of revenue 11,922 11,940 23,479...

  • Financial
    Osteotech Reports First Quarter 2010 Financial Results

    First Quarter Results Include 88% Sequential Sales Growth for New Products Company Reiterates 2010 Guidance EATONTOWN, N.J., May 10 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the first quarter ended March 31, 2010. "During the first...

  • Financial
    Osteotech Reports Fourth Quarter and Full Year 2009 Financial Results

    EATONTOWN, N.J., March 4 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the fourth quarter and full year ended December 31, 2009. Results were in-line with the limited, preliminary financial results the Company released on January 14,...

  • Financial
    Osteotech to Present at the Canaccord Adams Musculoskeletal Conference

    EATONTOWN, N.J., March 3 /PRNewswire-FirstCall/ — Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that its management team is scheduled to make a presentation on its business operations at the Canaccord Adams Musculoskeletal Conference at the Sheraton New Orleans Hotel in New Orleans, Louisiana on Tuesday, March 9,...

  • Uncategorized
    Osteotech vs. Apatech

    We have been hearing rumblings over the past few months about a war going on between Osteotech and Apatech. In head to head competition, Osteotech totals revenues of around $100 million while Apatech, although privately held, is rumored to have revenues north of $50 million. Osteotech is going through a constant change and...

  • Financial
    Healthcare Sector Stock Alert for Osteotech Inc. Issued by Beacon Equity

    DALLAS, Jan. 15, 2010 (GLOBE NEWSWIRE) — BeaconEquity.com announces an investment report featuring medical products maker Osteotech Inc. (Nasdaq:OSTE). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision. The full report is available at: http://www.beaconequity.com/i/OSTE Get our alerts BEFORE the...

  • Biologics
    Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix

    EATONTOWN, N.J., Dec. 17 /PRNewswire-FirstCall/ — Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that it has submitted a 510(k) application to the United States Food and Drug Administration (FDA) to obtain marketing clearance for the use of its Duratech™ BioRegeneration Matrix...

  • Biologics
    Osteotech’s Plexur M(R) Innovative Grafting Now Approved for Use at 50 U.S. Hospitals

    EATONTOWN, N.J., Dec. 1 /PRNewswire-FirstCall/ — Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that Plexur M® (moldable), a bone-polymer biocomposite built upon the Company’s proprietary Plexur® technology platform, has been approved for use by 50 U.S. hospitals to date. The Company...

  • Biologics
    Osteotech Reports Third Quarter 2009 Financial Results

    EATONTOWN, N.J., Nov. 5 /PRNewswire-FirstCall/ — Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the third quarter ended September 30, 2009. “During the third quarter of 2009, our focus was on the release of our three new biologic products...

  • Biologics
    Osteotech Secures 10-Year Tissue Supply Agreement

    EATONTOWN, N.J., Nov. 4 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products forregenerative healing, announced today that it entered into a multi-year tissue supply agreement with Community Tissue Services (CTS), with aninitial term spanning 10 years. This new agreement replaces an existing contract between the...

OrthoSpineNews is a publication run by Ortho Spine Companies which includes other brands like The De Angelis Group, Ortho Sales Partners, OrthoEx and Surg.io

We desire is to provide valuable content to the industry we love in an easy to read manner.

Copyright © 2018 OrthoSpineNews.

Themed By teapots